Ulcerative Colitis Chronic Moderate
14
4
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
83.3%
-3.2% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Study of Novel Therapeutics for Acute Remedy of Colitis
Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease
Combination of Diet and Oral Budesonide for Ulcerative Colitis
Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
Comparison Between Bowel Ultrasound-based Treat to Target Versus Routine Treat to Target Strategies in Ulcerative Colitis
Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis
Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients
Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO)
ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis
The Safety and Efficacy of TET Enema in the Treatment of UC
Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC